These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 27717506)

  • 1. The CRF System as a Therapeutic Target for Neuropsychiatric Disorders.
    Sanders J; Nemeroff C
    Trends Pharmacol Sci; 2016 Dec; 37(12):1045-1054. PubMed ID: 27717506
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Don't stress about CRF: assessing the translational failures of CRF
    Spierling SR; Zorrilla EP
    Psychopharmacology (Berl); 2017 May; 234(9-10):1467-1481. PubMed ID: 28265716
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure and Function of Small Non-Peptide CRF Antagonists and their Potential Clinical Use.
    Fahmy H; Kuppast B; Ismail MT
    Curr Mol Pharmacol; 2017; 10(4):270-281. PubMed ID: 27809751
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 3D-QSAR study of corticotropin-releasing factor 1 antagonists and pharmacophore-based drug design.
    Ye Y; Liao Q; Wei J; Gao Q
    Neurochem Int; 2010 Jan; 56(1):107-17. PubMed ID: 19782115
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Corticotropin-releasing factor (CRF) in stress and disease: a review of literature and treatment perspectives with special emphasis on psychiatric disorders.
    Krohg K; Hageman I; Jørgensen MB
    Nord J Psychiatry; 2008; 62(1):8-16. PubMed ID: 18389420
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cell type-specific modifications of corticotropin-releasing factor (CRF) and its type 1 receptor (CRF1) on startle behavior and sensorimotor gating.
    Flandreau E; Risbrough V; Lu A; Ableitner M; Geyer MA; Holsboer F; Deussing JM
    Psychoneuroendocrinology; 2015 Mar; 53():16-28. PubMed ID: 25575243
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent advances with the CRF1 receptor: design of small molecule inhibitors, receptor subtypes and clinical indications.
    McCarthy JR; Heinrichs SC; Grigoriadis DE
    Curr Pharm Des; 1999 May; 5(5):289-315. PubMed ID: 10213797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of the HPA axis in psychiatric disorders and CRF antagonists as potential treatments.
    Keller PA; McCluskey A; Morgan J; O'connor SM
    Arch Pharm (Weinheim); 2006 Jul; 339(7):346-55. PubMed ID: 16783839
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CRF signaling: molecular specificity for drug targeting in the CNS.
    Arzt E; Holsboer F
    Trends Pharmacol Sci; 2006 Oct; 27(10):531-8. PubMed ID: 16935354
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-affinity CRF1 receptor antagonist NBI-34041: preclinical and clinical data suggest safety and efficacy in attenuating elevated stress response.
    Ising M; Zimmermann US; Künzel HE; Uhr M; Foster AC; Learned-Coughlin SM; Holsboer F; Grigoriadis DE
    Neuropsychopharmacology; 2007 Sep; 32(9):1941-9. PubMed ID: 17287823
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biological intersection of sex, age, and environment in the corticotropin releasing factor (CRF) system and alcohol.
    Agoglia AE; Crofton EJ; Herman MA
    Neuropharmacology; 2020 Jun; 170():108045. PubMed ID: 32217364
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Corticotropin-releasing factor overexpression gives rise to sex differences in Alzheimer's disease-related signaling.
    Bangasser DA; Dong H; Carroll J; Plona Z; Ding H; Rodriguez L; McKennan C; Csernansky JG; Seeholzer SH; Valentino RJ
    Mol Psychiatry; 2017 Aug; 22(8):1126-1133. PubMed ID: 27752081
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monkey corticotropin-releasing factor1 receptor: Complementary DNA cloning and pharmacological characterization.
    Oshida Y; Ikeda Y; Chaki S; Okuyama S
    Life Sci; 2004 Feb; 74(15):1911-24. PubMed ID: 14761672
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of CRF1 receptor antagonists as antidepressants and anxiolytics: progress to date.
    Valdez GR
    CNS Drugs; 2006; 20(11):887-96. PubMed ID: 17044726
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Corticotrophin-releasing factor 1 activation in the central amygdale and visceral hyperalgesia.
    Taché Y
    Neurogastroenterol Motil; 2015 Jan; 27(1):1-6. PubMed ID: 25557223
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Corticotropin releasing factor receptor antagonists for major depressive disorder.
    Paez-Pereda M; Hausch F; Holsboer F
    Expert Opin Investig Drugs; 2011 Apr; 20(4):519-35. PubMed ID: 21395482
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis of substituted pyrimidines as corticotropin releasing factor (CRF) receptor ligands.
    Kuppast B; Spyridaki K; Liapakis G; Fahmy H
    Eur J Med Chem; 2014 May; 78():1-9. PubMed ID: 24675175
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging role of alternative splicing of CRF1 receptor in CRF signaling.
    Zmijewski MA; Slominski AT
    Acta Biochim Pol; 2010; 57(1):1-13. PubMed ID: 20234885
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Progress in corticotropin-releasing factor-1 antagonist development.
    Zorrilla EP; Koob GF
    Drug Discov Today; 2010 May; 15(9-10):371-83. PubMed ID: 20206287
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of corticotropin-releasing factor family peptides and receptors in stress-related psychiatric disorders.
    Clark MS; Kaiyala KJ
    Semin Clin Neuropsychiatry; 2003 Apr; 8(2):119-36. PubMed ID: 12728411
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.